A Cure In Sight is excited to announce the funding and launch of an important new uveal melanoma research project. ACIS, along with a generous financial gift from Jack Odell and John Dagres, will be funding a new arm of continuing research with Dr. J. William Harbour and Dr. Stefan Kurtenbach of the Harbour Ocular Oncology Laboratory at Bascom Palmer Eye Institute and Sylvester Comprehensive Cancer Center. The contract for this work is 1-year and will begin immediately, thanks to this joint donation totaling $100,000. This research is to investigate a strategy for determining the pathogenicity of “variants of unknown significance” in the GNA11 gene in UM development and metastases. Characterizing variants of unknown significance could have an important impact on targeted therapy.
From the Harbour Laboratory:
“This award will aid in establishing a methodology for screening variants of unknown significance in uveal melanoma. This specific methodology does not currently exist and will provide the foundation for future discoveries”.
Melody Kling, Founder-President
Jack Odell, Director of Special Projects
A Cure In Sight™